Physician

Naveen Trehan, MD

According to 2025 Medicare claims, Naveen Trehan, MD (NPI: 1285045526) practices nephrology in the Hot Springs, AR market, with the plurality of this provider's patient population coming from Garland, AR. This provider's primary affiliated billing organization is ARKANSAS RENAL GROUP PA (NPI: 1699043067; TIN: 45-3592104) and primary practice location at 71913-6406. Trehan is affiliated with the Baptist Health/UAMS Accountable Care Alliance (ACO ID: A3633), participating under the MSSP model.

Trehan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 549 traditional Medicare patients, billed 2,177 HCPCS/CPT codes, and received $243,762 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 2,647 prescription claims across 379 beneficiaries totaling $337,383 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 197 claims. Open Payments data shows 10 records totaling $260. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $4,792 to $337,383. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	310	777	$81,004
2021	772	2,262	$262,350
2022	536	1,934	$271,570
2023	450	1,442	$196,100
2024	549	2,177	$243,762

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	141	$4,792
2016	64	544	$43,504
2017	68	491	$51,406
2018	45	218	$14,767
2019	20	82	$6,392
2020	115	387	$22,766
2021	330	2,490	$206,766
2022	342	2,842	$283,010
2023	329	2,371	$364,218
2024	379	2,647	$337,383

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	158	$4,876
2022	N/R	190	$4,621
2023	N/R	172	$3,325
2024	N/R	197	$3,031

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	117	293	$153
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	139	190	$89
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	210	654	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	154	180	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	141	153	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	197	10,640	$197,595
Kerendia	Finerenone	18	1,320	$27,695
Torsemide	Torsemide	410	22,644	$7,453
Clonidine	Clonidine	54	2,016	$5,201
Sevelamer Carbonate	Sevelamer Carbonate	44	1,380	$4,116

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	67	$840
J7500	Azathioprine, oral, 50 mg	N	N/R	13	$763
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	36	$678
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	23	$398
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	40	$338

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$260	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Naveen Trehan, MD?

Tedicare shows public-source Medicare data for Naveen Trehan, MD (NPI 1285045526), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Naveen Trehan, MD have ACO affiliation data?

Naveen Trehan, MD is shown with ACO affiliation data for Baptist Health/UAMS Accountable Care Alliance (MSSP, ACO ID A3633).

What billing organization is linked to Naveen Trehan, MD?

Naveen Trehan, MD is linked to ARKANSAS RENAL GROUP PA (billing NPI 1699043067) in the available physician profile data.

Does Naveen Trehan, MD have Open Payments data?

Naveen Trehan, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.